全文获取类型
收费全文 | 1277篇 |
免费 | 85篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 61篇 |
妇产科学 | 10篇 |
基础医学 | 111篇 |
口腔科学 | 29篇 |
临床医学 | 199篇 |
内科学 | 394篇 |
皮肤病学 | 13篇 |
神经病学 | 56篇 |
特种医学 | 254篇 |
外科学 | 70篇 |
综合类 | 21篇 |
预防医学 | 42篇 |
眼科学 | 7篇 |
药学 | 42篇 |
中国医学 | 5篇 |
肿瘤学 | 55篇 |
出版年
2023年 | 10篇 |
2022年 | 6篇 |
2021年 | 15篇 |
2020年 | 11篇 |
2019年 | 7篇 |
2018年 | 30篇 |
2017年 | 16篇 |
2016年 | 33篇 |
2015年 | 28篇 |
2014年 | 36篇 |
2013年 | 48篇 |
2012年 | 33篇 |
2011年 | 31篇 |
2010年 | 47篇 |
2009年 | 66篇 |
2008年 | 43篇 |
2007年 | 24篇 |
2006年 | 25篇 |
2005年 | 21篇 |
2004年 | 27篇 |
2003年 | 23篇 |
2002年 | 20篇 |
2001年 | 26篇 |
2000年 | 29篇 |
1999年 | 18篇 |
1998年 | 54篇 |
1997年 | 56篇 |
1996年 | 65篇 |
1995年 | 52篇 |
1994年 | 45篇 |
1993年 | 50篇 |
1992年 | 25篇 |
1991年 | 21篇 |
1990年 | 25篇 |
1989年 | 43篇 |
1988年 | 34篇 |
1987年 | 35篇 |
1986年 | 41篇 |
1985年 | 26篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 11篇 |
1975年 | 14篇 |
1974年 | 5篇 |
排序方式: 共有1372条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Nicola Martinelli Domenico Girelli Paolo Ferraresi Oliviero Olivieri Barbara Lunghi Franco Manzato Roberto Corrocher Francesco Bernardi 《Blood coagulation & fibrinolysis》2007,18(2):125-129
A common factor V gene haplotype, the FVR2 haplotype (FVHR2), has been associated with a reduced cofactor activity in activated protein C-mediated activated factor VIII inactivation. Our aim was to investigate the role of FVHR2 as a possible determinant of factor VIII levels in a population study. A total of 516 individuals (401 men, 115 women; mean age 58.4 +/- 10.8 years) were enrolled within the frame of a regional cardiovascular survey, characterized for factor VIII coagulant activity (FVIII:c) and factor V coagulant activity (FV:c) levels, and genotyped for factor V polymorphisms. In men without signs of overt inflammation, FVHR2 carriers had higher levels of FVIII:c than noncarriers (154 IU/dl, 95% confidence interval = 143-166 versus 142 IU/dl, 95% confidence interval = 138-147; P = 0.045) and were more represented in individuals with high (> or = 150 IU/dl) FVIII:c levels (21.2 versus 10.8%; odds ratio = 2.27, 95% confidence interval = 1.17-4.39 after adjustment for age, blood group and high-sensitivity C-reactive protein levels). In conclusion, this clinical report suggests the common FVHR2 as a possible independent determinant of FVIII:c levels. The report concomitantly addresses the relationship between factor V and factor VIII levels and supports the hypothesis of a mild prothrombotic role of FVHR2 by means of increased factor VIII levels. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.